Clinical Trial Search

Primary: Change in Eczema Area and Severity Index (EASI)Scores According to Location — -1.06; -0.57; -4.94; -0.88 Change in EASI Score

Primary: Incidence of Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Deaths and Discontinuations Due to Adverse Events (AEs) — 1 incidence

Primary: Number of Participants With PGA of 0 or 1 — 22; 14 participants — p=0.035

Primary: Clinical Outcome in Participants With Baseline Methicillin Resistant Staphylococcus Aureus (MRSA) at End of Study (EOS) for PP Population — 95; 81; 70; 93 Participants…

Primary: Assessment of Safety Through Clinical Examinations, Clinical Laboratory Results, Self-reported Diary Reactogenicity Data and Adverse Event Reports — 37; 40; 28; 36 events

Primary: Relative Abundance of Staphylococcus Aureus Compared to Baseline — 0.106; 12.9 Relative abundance of S. aureus

Primary: Incidence of Adverse Events [Safety and Tolerability] — 48; 30; 64; 40 Participants

Primary: Relative Staphylococcus Aureus Abundance — 0.13; 12.2 ratio to baseline S. aureus abundance

Primary: Number of Participants With Eradiction of S. Aureus From the Oropharyngeal at 7 Days — 18; 7 Participants

Primary: Percentage of Participants Achieving Clinical Cure, Defined as Absence of Clinical Failure, in the Evaluable Population. — 89.5; 88.2; 92.9; 92.7 percentage of…

Primary: Number of Participants With One or More Adverse Events (AEs) — 15; 6; 12; 9 Participants

Primary: Plasma Retapumulin Pharmacokinetic Parameters by Treatment at Days 1 and 3 Evaluated by Plasma AUC After Dosing — 0.8663; 0.3816; 4.2802; 2.0881 ng.h /mL

Primary: Efficacy Adjudication Committee (EAC) Assessment of Number of Participants With Clinical Success at Test of Cure (TOC) — 45; 16; 2 Participants

Primary: Clinical Response at Test of Cure (TOC) — 86.2; 80.0; 0.0; 6.9 Percentage of participants

Primary: Number of Patients With or Without Overall Success at the Post-treatment Evaluation (PTE) Visit — 132; 136; 57; 62 Participants